Crossbow Therapeutics, Inc
Jennifer Helble is a highly skilled scientist with extensive experience in immunology and biotechnology. Currently serving as a Senior Scientist at Crossbow Therapeutics, Inc., Jennifer has previously contributed as a Scientist II at Celsius Therapeutics, where multiple pre-clinical projects in inflammatory bowel disease (IBD) and oncology were advanced through designing co-culture assays and making key program decisions. Jennifer's academic background includes a Ph.D. in Immunology from Harvard University, where research focused on antigen-specific CD4+ T cell responses, and a B.A. in Biochemistry from Bowdoin College. Additional experience encompasses postdoctoral research at Tufts University, adjunct teaching at Emmanuel College, and various research assistant roles.
Crossbow Therapeutics, Inc
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.